A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Clinical trial NCT06829459 · RECRUITING
Trial details
- NCT number
- NCT06829459
- Sponsor
- Shanghai JMT-Bio Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-03
- Primary completion
- 2028-02-15
- Enrollment
- 350
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.